FBC, in collaboration with US firm Morgan, Lewis & Bockius, represented Perrigo Company in the sale of its active pharmaceutical ingredients business headquartered in Israel for a purchase price of US$110 million. The transaction included the sale of all of the share capital of Perrigo API Ltd. and Perrigo API USA Inc., as well as the R&D based in India.
The sale was executed through an auction process, with negotiations being conducted with several bidders’ and involved matters covering tax issues, labor and union matters and other matters.
Perrigo API is a world-class developer and manufacturer of Active Pharmaceuticals Ingredients and select Finish Dosage Forms for the branded and generic pharmaceutical industries. Perrigo API comprises the majority of Perrigo’s business in Israel, with over 300 employees.
Press on the matter, click here